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Abstract
We live in a world with an ever-increasing ageing population. Studying healthy ageing and reducing the
socioeconomic impact of age-related diseases is a key research priority for the industrialised and developing
countries, along with a better mechanistic understanding of the physiology and pathophysiology of ageing that
occurs in a number of age-related musculoskeletal disorders. Arthritis and musculoskeletal disorders constitute a
major cause of disability and morbidity globally and result in enormous costs for our health and social-care systems.
By gaining a better understanding of healthy musculoskeletal ageing and the risk factors associated with premature
ageing and senescence, we can provide better care and develop new and better-targeted therapies for common
musculoskeletal disorders. This review is the outcome of a two-day multidisciplinary, international workshop
sponsored by the Institute of Advanced Studies entitled “Musculoskeletal Health in the 21st Century” and held at
the University of Surrey from 30th June-1st July 2015.
The aim of this narrative review is to summarise current knowledge of musculoskeletal health, ageing and disease
and highlight strategies for prevention and reducing the impact of common musculoskeletal diseases.
Keywords: Ageing, Musculoskeletal health, Musculoskeletal disorders, Global burden, Joint diseases, Osteoarthritis
(OA), Rheumatoid arthritis (RA), Low back pain (LBP), Osteoporosis (OP), Sarcopenia, Obesity, Type II diabetes,
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Background
The current rise in life-expectancy, the subsequent in-
crease in numbers of older people and increasing pen-
sion costs have prompted the UK government to change
policy, extend working years and delay pensionable age.
By 2034 the number of people in the UK aged 85 and
over is projected to be 2.5-times larger than in 2009,
reaching 3.5 million and accounting for 5 % of the popu-
lation. The number of people aged 65+ is expected to
rise to over 16 million in the UK by the same time point
(according to Age UK and the Office for National Statis-
tics [1]). However, working for an extended period of
time may not be feasible for those with major, or
chronic, health problems. As careers are extended in dif-
ferent sectors, special attention will need to be paid to
addressing the workplace needs of those with major
health problems. According to the UK Department of
Health and Age UK, 58% of those aged 60 and over re-
port having a long-term condition, with 25% of over 60s
having two or more health problems [1, 2]. This means
that the majority of those aged 60 to retirement will
already have multiple morbidities. Of these conditions,
musculoskeletal diseases are considered to be one of the
highest global burdens on individuals, health and
social-care systems [3–6] (Fig. 1 a and b). It is important to
note that although there is some epidemiological informa-
tion about the burden of musculoskeletal disease in India
[7, 8] and China [9] through COPCORD (Community ori-
ented program from control of rheumatic diseases), equiva-
lent, up-to-date and accurate epidemiological data does not
exist for Central America, South America and Sub-Saharan
Africa. Therefore, the true global burden of musculoskeletal
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disease is likely to be grossly underestimated. Com-
mon musculoskeletal conditions include osteoarthritis
(OA), rheumatoid arthritis (RA), psoriatic arthritis
(PsA), gout, lower back pain (LBP) and osteoporosis
(OP). Between the fifth and ninth decade of life, OA
and LBP are major contributors to musculoskeletal
impairment (Fig. 1 c). Arthritis is of particular con-
cern for the UK population as some 10 million
people are now estimated to be suffering from the
condition. Public Health England has published guide-
lines for evidence-based interventions to reduce the
impact of LBP, falls and OA (Fig. 2). OA is the most
common form of arthritis and the key risk factors are
age, obesity, metabolic disease and prior joint injury.
RA is an inflammatory joint disease with a strong
genetic and immune basis that affects approximately
1% of the total global population. The incidence of
OA and RA increases with age, as does LBP [10].
Fig. 1 a The global burden of hip and knee osteoarthritis; estimates from the Global Burden of Disease Study 2010. The numbers show the
number of case studies reported in the literature for each country, extracted via a systematic review process. Reproduced from Cross M, Smith E,
Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Note the absence of data
from Central America, South America and Sub-Saharan Africa. Annals of the Rheumatic Diseases Published Online First: 19 February 2014. doi:
https://doi.org/10.1136/annrheumdis-2013-204,763. b. The global burden of musculoskeletal disease attributable to low bone mineral density. The
numbers show the number of case studies reported in the literature for each country, extracted via a systematic review process. Reproduced
from Sànchez-Riera L, Carnahan E, Vos T, et al. The global burden attributable to low bone mineral density Annals of the Rheumatic Diseases
Published Online First: 01 April 2014. doi: https://doi.org/10.1136/annrheumdis-2013-204,320. c. The prevalence rheumatic and musculoskeletal
diseases in France. This figure highlights the dominance of osteoarthritis and back pain from the fifth to the 9th decade of life. Reproduced from
Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S (2014) The Burden of Musculoskeletal Conditions. PLOS ONE 9(3):
e90633. https://doi.org/10.1371/journal.pone.0090633
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This narrative review is the outcome of a multidiscip-
linary, international workshop sponsored by the Institute
of Advanced Studies (IAS) entitled: “Musculoskeletal
Health in the 21st Century” and held at the University of
Surrey, UK, from 30th June-1st July 2015. The abstracts
from this workshop were published in a special supple-
ment of BMC Musculoskeletal Disorders in 2015. [11].
Diverse topics were discussed and debated, ranging from
the global burden of OA to the link between diabetes
and joint disease, diet and nutrition in arthritis, One
Health [12], ageing, advances in imaging and musculo-
skeletal health and disease in military personnel and
companion animals. One of the key deliverables of the
international workshop was a paper that summarised
the topics that were discussed. In this paper, we sum-
marise and disseminate some of the key outcomes from
the workshop in the context of currently available infor-
mation, discuss the current challenges faced by society
in relation to the rising burden of musculoskeletal disor-
ders and review existing strategies and recommendations
for prevention and mitigation of the impact of these
diseases.
The workshop reached an important consensus state-
ment, namely that development of more precise diag-
nostic and prognostic tools and targeted treatments is
necessary, along with better disseminated preventative
measures, which is in complete alignment with those
outlined by the Arthritis Research UK (now rebranded as
Versus Arthritis) approach plan (2014). In order to
achieve this, greater transfer and translation of know-
ledge between the veterinary and human fields is
needed as well as more funding for musculoskeletal
research and investigation of populations with rare
diseases and those with higher incidences of joint in-
juries, such as youth sport and the military.
Current societal challenges
Physical inactivity and sedentary behaviour
Sedentary behaviour and the rapid growth of legions of video
game, social media and movie-streaming addicted couch po-
tatoes is a consequence of sustained and systemic urbanisa-
tion in developed countries, including the United States,
where nearly 50% of the population do not undertake
even the bare minimum levels of aerobic activity rec-
ommended by Physical Activity Guidelines [13]. This
rise in sedentary behaviour is seen as a major risk factor
for a number of chronic diseases recognised by the Na-
tional Health Service (NHS), costing around £1billion a
year in the UK, and is recognised as a substantial global
economic burden [14]. Statistics recently provided by
the Centre for Economics and Business Research show
the cost of “doing nothing”: half a million Europeans
die every year as a result of being physically inactive
and this costs the economy over €80bn annually [15].
This global challenge requires urgent and feasible solu-
tions. Increasing physical activity and optimising exer-
cise (as recommended by Arthritis Research UK/Versus
Arthritis and World Health Organisation (WHO)) is
seen as an optimal way to improve musculoskeletal
health. Only 36% of the adult population in the UK take
part in moderate intensity physical activity of about 30
min at least once a week [16]. An increasing body of
evidence is showing that even the effects of a sedentary
lifestyle (for example, of those with a desk job) can be
mitigated by a small amount of activity every day. A re-
cent meta-analysis of the data from studies involving
Fig. 2 Evidence-based interventions for the musculoskeletal conditions that cause the most DALYs (Disability-adjusted life years) in England,
including low back and neck pain, falls and
osteoarthritis. https://publichealthmatters.blog.gov.uk/2016/01/11/preventing-musculoskeletal-disorders-has-wider-impacts-for-public-health/
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over 1 million individuals concluded that an hour of
moderate level activity per day eliminated the in-
creased risk of death associated with 8 h of sitting
[17]. Interestingly, the study also found that these
levels of activity did not have an effect on the in-
creased risk of death associated with high levels of
leisure-time sedentary behaviour such as watching
television. Whilst this level of activity is far more
than those recommended by WHO, it is clear that
keeping a moderate level of physical activity is a key
requirement for healthy ageing and maintaining mus-
culoskeletal health [17]. WHO recommendations sug-
gest that healthy individuals should take around two
hours a week of moderate physical activity or ap-
proximately 20 min a day of doing any kind of phys-
ical activity like brisk walking. This level of exercise,
which involves elevation of heart-rate, has been asso-
ciated with lower lifetime risk of cardiovascular dis-
ease in a 25 year longitudinal study of approximately
13,000 adults [18]. In addition to benefits for muscu-
loskeletal health, improvements in cardiorespiratory
fitness can be achieved by changing sedentary behav-
iour to achieve a low-intensity physical activity such
as walking [19]. Furthermore, in patients with knee
OA, improvement of locomotor function, including
balance and strength, and a reduction in pain was
seen following supplementation of home exercise with
an eight-week class-based programme [20]. Patients
suffering with chronic LBP who were given an exer-
cise programme combining muscle strength, flexibility
and aerobic fitness also reported a reduction in stiff-
ness, which can result in back pain [21]. The idea of
exercise for rehabilitation of musculoskeletal injuries
has been widely accepted for many years now, and
the idea of prescribing exercise as a preventative
health measure is also more widely investigated, with
guidelines around the type, frequency and duration of
activity being considered [22].
Sedentary behaviour is also contributing to the rise
in obesity and type-2 diabetes. Obesity is a major
contributor to the development and progression of
OA [23] and numerous epidemiological studies have
confirmed the link between adiposity and joint degen-
eration. The prevalence of diabetes mellitus is be-
tween 7 and 14% globally [24]. Diabetes is an
important predictor for severe forms of arthritis [25]
and has recently been shown to be an independent
risk factor for the progression of OA in men [26].
This shows that measures to increase levels of phys-
ical activity will not only increase musculoskeletal
(MSK) health but also decrease the risk of suffering
from obesity-related diseases such as diabetes. This
will reduce the numbers in the population susceptible
to MSK disorders and ill health.
Healthy ageing and physical exercise
Whilst ageing is inevitable, the benefits of exercise on
the ageing body are numerous and, in some circum-
stances, can reduce the manifestations of ageing, particu-
larly the "ageing phenotype" of the elderly. A recent
systematic review looked at evidence supporting nutrition
and physical activity in the prevention and treatment of
sarcopenia [27]. Sarcopenia results in loss of muscle
strength and mass and this can lead to weakening of mus-
culoskeletal structures and impair tendon, ligament, bone
and cartilage function, which will destabilise the joint and
increase the risk of arthritis and other musculoskeletal dis-
orders. The authors identified a total of 37 randomised
control trials to explore the effect of combined exercise
and nutritional intervention for overcoming muscle sarco-
penia. They concluded that physical exercise has a positive
impact on muscle mass and function in healthy subjects
aged 60 and above, however, there were huge variations in
outcomes connected with dietary supplementation,
highlighting the difficulties associated with cohort studies
of well-nourished human beings, where the interactive ef-
fects of dietary supplementation may be masked or com-
pletely limited [27]. Physical exercise improves muscle
performance by increasing the ratio of type I to type II
muscle fibres and increasing the cross-sectional area of
type II muscle fibres [28].
A European Society for Clinical and Economic Aspects
of Osteoporosis, Osteoarthritis and Musculoskeletal Dis-
eases (ESCEO) taskforce looked at dietary protein and
vitamin D and calcium supplementation and recom-
mended higher protein intake in combination with phys-
ical exercise particularly in post-menopausal women at
risk of developing menopause-associated musculoskeletal
disease, such as OP [29]. Physical exercise programmes
improve strength and balance in ageing women with OP
[30]. Fragility fracture risk, associated with OP, can be de-
creased by following an exercise programme, as exercise
increases bone density and reduces inflammatory markers
[31]. However, the incidence of OP is usually highest in
elderly females who are most unlikely to perform the dy-
namic exercises needed for bone modelling/remodelling
[32]. This highlights the challenge of preventing OP and
OP-related fractures in elderly females that cannot per-
form ballistic exercise. Some medications are available
for these frail patients but having an active lifestyle
from an early age and following recommendations for
exercise could be more beneficial. The same principle
applies to frailty in ageing companion animals, where
life-long spontaneous exercise significantly slows
down the progression of frailty [33].
Physical activity is also known to increase insulin me-
diated glucose uptake and, in individuals without type-2
diabetes, exercise positively impacts on systemic glucose
homeostasis. However, in patients with type-2 diabetes
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where beta-cell impairment is significant, physical train-
ing does not decrease insulin secretion [34]. A recent
study found that a 30 min daily increment in moderate
to vigorous intensity physical activity also significantly
reduced glycated haemoglobin, a measure of type-2 dia-
betes risk [19]. Physical exercise reduces the risk of car-
diovascular and metabolic comorbidities associated with
joint diseases.
In addition to the positive effects of exercise on phys-
ical and mental well-being, there is also ample evidence
to suggest that exercise and mechanical loading have a
positive impact at the molecular, cellular and tissue
levels. For example, in tendons, where ageing decreases
the potential for cell proliferation and number of stem/
progenitor-like cells, it has been shown that exercise/
loading can induce an increase in tendon collagen syn-
thesis [35], increasing tendon strength. In an animal
model of ageing, it was found that moderate exercise
could also enhance the quality of tissue produced during
healing of injured tendons [36]. There is plenty of pub-
lished evidence to support a positive role for physical ex-
ercise and mechanical loading for cartilage [37] and
bone health [38].
Obesity
The rise in sedentary behaviour and unhealthy diets con-
tributes to the global obesity epidemic and the sharp rise
in the incidence of type-2 diabetes. When combined
these are powerful risk factors for cardiovascular and
neurodegenerative diseases, which further complicates
the management of musculoskeletal diseases. As with
physical inactivity, the NHS now recognises obesity as
an independent major risk factor for population
ill-health, costing the UK over £5billion. Obesity is
thought to be a key co-morbidity of many musculoskel-
etal conditions and is closely related to the development
of OA, one of the commonest musculoskeletal health is-
sues. Reducing levels of obesity in the adult population
may lead to reduced occurrence of OA and can alleviate
some of the pain of the condition. Obesity also happens
to be one of the most modifiable risk factors for OA
[39]. Exercise and weight loss has been successfully
trialled in overweight and obese adults with knee OA
[40]. There are ongoing trials assessing the effects of
combined physical activity and weight loss and it will be
interesting to see how combining exercise and weight
loss may act synergistically to improve musculoskeletal
function. It is now clear that combining modest weight
loss with moderate exercise can provide the best overall
improvement in symptoms of pain and joint function.
Furthermore, improved diet, moderate exercise and
weight loss are probably the best short-term solutions
for the ineffective surgical interventions for OA patients.
Childhood obesity and physical inactivity
Reducing obesity in children may also reduce the risk of
developing musculoskeletal pain later in life [41], al-
though the full impact of obesity on development of the
child’s musculoskeletal system is still poorly understood
[42]. A major contributor to the obesity epidemic is the
lack of physical exercise in the population, with many
people leading an increasingly sedentary lifestyle. Simi-
larly, unhealthy diets are a common problem, due to the
ready availability of a bewildering variety and quantity of
fast foods, ready meals and the relentless advertising of
these products. The low nutritional value and high cal-
orie content of these foods further contributes to the
obesity epidemic. They may also play a role in the high
prevalence of type-2 diabetes and cardiovascular diseases
which are exacerbated by a lack of fitness and by
inactivity.
The companion animal link
The health issues that impact on society are not just lim-
ited to humans. We co-exist with a variety of companion
animals and share the same diet and environment. In a
study of approximately 700 dogs, 40% were overweight
and 20% obese [43]. In addition, there is a strong correl-
ation between the canine obesity and the BMI of their
owners, indicating that the lifestyle and diet of the
owners is having a direct impact on their pets as they
share the same environment, and probably with similar
impacts on their families [44]. This highlights an oppor-
tunity for vets and medics to collaborate to tackle obes-
ity, diabetes and cardiovascular co-morbidities that
impact on humans and their companion animals.
Dietary factors
It is generally accepted that maintaining a healthy weight
can help to improve musculoskeletal health and prevent
degenerative diseases, but research also focuses on
whether dietary factors can influence disease progres-
sion. Eating a varied diet high in fresh fruit and vegeta-
bles is recommended by many health organisations. A
combined regime of exercise and increased intake of
fruit and vegetables increased life expectancy in women;
those in their 70s with the highest level of activity and
vegetable consumption were eight-times more likely to
survive a five-year follow up period [45]. However, few
direct links between fruit and vegetable intake and im-
proved musculoskeletal health have been shown but one
three year follow-up study of nearly 400 adults showed
that diets high in potassium (from fruit and vegetable in-
take) reduced the amount of muscle loss in adults > 65
years [46]. Dietary flavonoid intake, the compound
found in many fruit and vegetables, was positively corre-
lated with good bone health (measured by bone mineral
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density and bone resorption) in a population of
peri-menopausal women [47].
As current treatment options in OA are very limited,
OA patients may benefit from the ability to self-manage
their condition through improving their diet [48]. Vita-
min D, calcium and protein (particularly protein) opti-
mise muscle, bone and functional outcomes in older
people reducing falls and fractures [49]. Calcium and
protein intake work together to optimise bone health
[50]. Previously, it was thought that, in older patients,
diets too high in protein should be avoided due to the
detrimental effect on the kidneys. However, increasing
evidence now shows that protein levels should not be
decreased, as the effects of metabolic acidosis on the
kidneys can be offset by increased fruit and vegetable in-
take (as these foods decrease renal acid load) [51, 52].
Several studies recommend the benefits of supple-
menting the diet with “nutraceuticals”. A recent system-
atic review found promising but nevertheless limited
research evidence to support the oral use of several
herbal supplements including Boswellia serrata extract
and pycnogenol, curcumin and methylsulfonylmethane
in people with OA despite the poor quality of the pub-
lished studies [53]. Dietary strategies for improving mus-
culoskeletal health can include consumption of
long-chain fatty acids and vitamins D and K [54, 55] as
well as decreasing blood cholesterol [56]. OA patients
should ensure that they meet the recommended intakes
for micronutrients such as vitamin K, which has a role
in bone and cartilage mineralization. However, the cur-
rently available evidence for a role of vitamin D supple-
mentation in OA is unconvincing [48]. Research has
focussed on a number of dietary supplements to modu-
late progression of the disease or ease joint stiffness (and
therefore pain). A diet rich in antioxidants may provide
a useful therapeutic tool for athletes, improving tissue
repair, although the optimum dosage is unknown [57].
Combining exercise with a dietary supplement of whey
protein fortified with vitamin D is effective at increasing
muscle mass and strength in elderly people affected with
sarcopenia [58].
Both human and veterinary research has shown prom-
ise for a number of other natural products or com-
pounds derived from natural sources for alleviation of
arthritic symptoms. Green-lipped mussel extract has
been shown to be an effective chondroprotective agent
[59], reducing OA symptoms in dogs with OA [60].
More recently, fish oil and krill oil have been found to
have even greater protective effects against proteoglycan
and collagen degradation in an in vitro model of canine
arthritis [61]. These substances are all known to be rich
in long-chain omega-3 polyunsaturated fatty acids. A
separate study found that supplementing the diet of dogs
with eicosapentaenoic acid and docosahexaenoic acid
(both long-chain omega-3 polyunsaturated fatty acids)
significantly reduced the clinical signs of OA [62]. In
humans, these substances have also been demonstrated
to provide an alternative to anti-inflammatory pain med-
ications for the relief of chronic neck and back pain as
well as joint pain in rheumatoid arthritis [63, 64]. Whilst
the molecular mechanism of action of these fatty acids is
not entirely understood, it has been shown that these
compounds reduce the expression of cartilage-degrading
proteases and inflammatory cytokines [65].
Curcumin is a well-known plant-derived compound
with anti-oxidant and anti-inflammatory properties. Its
effects have been described in numerous chronic ill-
nesses in humans, including diabetes, allergies and arth-
ritis. It modulates growth factors, transcription factors
and inflammatory cytokines [66]. Interestingly, a recent
systematic review, has investigated the efficacy and safety
of dietary supplements for OA human patients and
found that lesser known supplements such as curcumin
from Curcuma longa and Boswellic acid from Boswellia
serrata were more effective than well-known nutraceuti-
cals, such as glucosamine and chondroitin [67]. Glucosa-
mine and chondroitin are popular supplements that
have been suggested to promote healthy joint function.
However, there is little evidence of their benefit [67].
Glucosamine was recommended in early guidelines is-
sued by the European League Against Rheumatism
(EULAR) and the Osteoarthritis Research Society Inter-
national (OARSI) for the management of knee OA [68,
69] but it was not recommended in the National Insti-
tute for Health and Care Excellence (NICE) guidelines
and in the most recent set of OARSI recommendations
it was identified as being “uncertain” [70]. More recent
guidelines published by EULAR, OARSI and ACR do
not recommend glucosamine.
In vitro evidence for glucosamine is generally good. At
relatively high concentrations, glucosamine has been
shown to have a protective effect on cartilage and syn-
ovial fluid; however many clinical trials have shown that
this substance is unable to reach the tissue that it is
meant to affect in appropriate and sufficient doses [68].
Structural heterogeneity of chondroitin sulphate, another
supplement commonly taken alongside glucosamine,
means that it is difficult to see consistent effects of this
supplement, and the supplements available on the mar-
ket are unlikely to be pure due to contamination with
other glycosaminoglycans during the manufacturing
process [71]. There is some evidence that glucosamine
and chondroitin sulphate together provide superior ef-
fects on the inhibition of nitric oxide and prostaglandin
synthesis and on protection of cartilage structure, than
when applied alone [72, 73]. This combination may also
be effective with the addition of manganese ascorbate, as
shown in patients with knee OA [74]. However, this is
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again in an in vitro model, so it is doubtful that these
substances would reach the required tissues at an appro-
priate dose. A small number of studies have found side
effects of glucosamine and chondroitin sulphate treat-
ment, which include inducing insulin resistance and glu-
cose metabolism disorders [75]. There is also concern
over the formulation of glucosamine, as it is commonly
given as a salt (glucosamine sulphate potassium/sodium
chloride) which could affect renal function, particularly
in elderly patients, who are arguably more likely to be
taking the supplement [68].
The gut microbiome is also an area of increasing focus
for health research. There is an association between The
Western Ontario and McMaster Universities Osteoarth-
ritis Index (WOMAC) pain scores of hip and knee OA
and the gut microbiome of individuals [76], so possible
future dietary interventions for OA could include main-
taining a healthy gut flora. Since dysbiosis of the intes-
tinal microbiota is strongly associated with the
pathogenesis of several metabolic and inflammatory dis-
eases, it is conceivable that also the pathogenesis of OA
might be related to it. However, the mechanisms and the
contribution of intestinal microbiota metabolites to OA
pathogenesis are still not clear [77]. Other foods and
food supplements, such as blueberry leaves and milk
thistle, have been found to have an anti-inflammatory or
anti-oxidant effect in other body systems, however the
effect of their function on the musculoskeletal system is
yet to be realised [78, 79].
Other co-morbidities and musculoskeletal disorders
There is increasing awareness of the effects of the pain
from musculoskeletal disorders on mental health. A
study on the effects of musculoskeletal chronic pain of
5900 individuals (including fibromyalgia or chronic back
or neck pain) indicated that they are at increased risk of
poor mental health and diminished quality of life com-
pared to those who did not report suffering from these
conditions [80]. Whilst the links between mental health
and musculoskeletal disorders are complex, it is thought
that living with the pain of OA can lead to depression
and anxiety; conversely, psychological distress and de-
pression worsen pain [81–83]. This can develop into a
vicious cycle with worsening pain and low mood. An
Australian study has found a strong association between
musculoskeletal health and mental health; 470,000 more
Australians had both a musculoskeletal condition and a
mental disorder than would be expected if occurrences
of the two conditions were independent of each other
[84]. Chronic insomnia can also indicate musculoskeletal
pain, as the two commonly co-occur, and doctors should
enquire about sleep patterns in patients consulting with
pain conditions [85].
A significant number of people suffering from OA also
have OP, which affects approximately 3 million people in
the UK. However, it was found that unless bone mineral
density measurements were taken from sites other than
the OA affected joints, there was a high likelihood of an
osteoporosis diagnosis being missed [86]. Another mus-
culoskeletal disorder, fibromyalgia, is often associated
with chronic fatigue, sleep disorders, irritable bowel syn-
drome and other psychological disorders, as well as car-
diovascular dysregulation [87].
Chronic musculoskeletal disorders can also aggravate
other disease conditions, due to their activity-limiting ef-
fects. Where patients are diagnosed with a musculoskel-
etal condition, it often means that they will have limited
mobility or that activity is painful to them. This restric-
tion of movement can then cause other ill health, such
as obesity or diabetes, or contribute to the effects of re-
spiratory disease [88]. For example, in a population of
war veterans, arthritis was shown to be associated with
diabetes, obesity and cardiovascular comorbidities [89].
Obesity has also been shown to reduce the efficacy of
anti-TNF treatment in rheumatoid arthritis [90].
Diagnostic and prognostic tools for
understanding mechanisms of disease
Biomarkers are routinely being used for diagnosis of
various diseases. These can include imaging techniques,
as well as detection and measurement of biochemical
markers found in the blood and urine. Currently most
OA diagnoses are made by radiography, once the patient
has presented with severe joint pain, by which point
there is little the clinician can do except manage that
pain at some level. Biomarkers for early diagnosis of dis-
eases could help to detect at-risk individuals and they
could then be put onto treatment plans to help prevent
further development of disease. Currently diagnosis of
OA, for example, is generally confirmed using imaging
techniques such as radiography [91]. Ultrasound is com-
monly used for diagnosis of soft tissue disorders such as
myopathies [92]. Magnetic Resonance Imaging (MRI)
and Computed Tomography (CT) can also be useful im-
aging techniques, however these more expensive
methods are less frequently used. MRI is the only one of
these techniques that is capable of assessing all the
structures of the joint, including cartilage and ligaments,
in 3D [91]. Radiography and CT techniques can be lim-
ited, however, as the degree of joint damage seen does
not necessarily correlate with the pain the individual is
experiencing, or the actual degree of cartilage damage,
for example. Radiographic diagnosis of arthritis can be
determined by joint space width measurements and
osteophyte development [93]. Ultrasound can also pro-
vide a useful view of the different tissues within a joint,
as it can provide a view on early inflammatory features
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and allows for detailed measurements of the joint
structures [94]. Development of more sophisticated
imaging techniques and image analysis tools is neces-
sary to correctly diagnose stages of musculoskeletal
diseases. While some techniques can distinguish small
changes in joint tissues during disease, it is unclear
how these correlate to specific grades of musculoskel-
etal conditions [95]. A technique that is starting to re-
ceive more attention is the use of non-invasive probes for
monitoring joint damage and inflammation. Radiotracers,
or contrast agents, are used for detecting inflammation to
provide a method for detection of specific subtypes of in-
flammatory activity in musculoskeletal conditions, by pro-
viding earlier and more reliable assessments of tissue
inflammation [96].
Gait analysis can be used as a biofeedback marker of
musculoskeletal health as it provides physical functional
outcome measures to quantify improvement, monitor
treatment and can provide early diagnosis of mechanical
compensation due to patient pain or discomfort. Diverse
gait-analysis technologies have been developed and used
in humans and sport horses over the past 40 years, and
are constantly being refined to provide reliable measures
of improvement from disease [97]. Current technologies
include wearables, inertial measurement units or acceler-
ometers which are lightweight, wireless devices to investi-
gate activity levels, gait patterns and fitness parameters for
humans and other animals [98–100]. Real-time or
delayed-time parameters that can be analysed include
ground reaction forces and foot-pressure distribution, the
kinematics of joints and segments, along with dynamic
electromyograms [101]. The information gained from
these analyses enables clinicians to quantify, and
therefore monitor and evaluate, gait and posture pa-
rameters such as asymmetry and other abnormal
movement patterns, possibly indicating pain or dis-
comfort in the musculoskeletal system. Increasing evi-
dence indicates that cytokines and mediators together
with mechanical stress are key to the development of
cartilage damage; this mechanical stress due to abnor-
mal movement patterns can also be quantified by gait
analyses [37]. Gait analysis has great clinical value as
a test for patients with neurological and orthopaedic
disorders as it provides quantifiable, objective, data to
aid the clinician in selection of any surgical procedure
needed and then to monitor outcomes and follow up
post-surgery. This is a valuable addition to the use of
traditional clinical examination. Nowadays, more ac-
curate and user-friendly technology for gait analysis
allows investigation of musculoskeletal diseases in hu-
man patients [101] and other species, with the goal of
obtaining a better definition of specific clinical hall-
marks of diseases such as rheumatoid arthritis [102]
and OA [103–105].
Imaging tools, diagnostic biomarkers and gait ana-
lysis should be combined for a more integrated ap-
proach to diagnosis of musculoskeletal disorders to
ensure that the clinician not only has a clear and
quantifiable overview of the patient’s clinical signs,
but is also able to consider what is happening at a
molecular and tissue level.
Management of musculoskeletal diseases
Common musculoskeletal disorders include LBP, fibro-
myalgia, gout, OA, tendinitis and RA. These result in
pain and disability, affecting quality of life and product-
ivity. To address this, Arthritis Research UK, recently
rebranded as Versus Arthritis in the UK, has developed
several recommendations to improve musculoskeletal
health, including advice on diet and lifestyle as preventa-
tive measures [41]. However, none of these recommen-
dations is related to actual treatment of disease or
improvement of diagnostic tools. Treatment of OA, for
example, currently only consists of pain management,
which is often insufficient, whilst diagnosis is generally
limited to clinical examination by a general practitioner
or, in some cases, diagnostic imaging.
Management of musculoskeletal diseases should start
with proper and complete pain management, including
accurate diagnosis and grading of pain [106]. As discussed
previously, pain from musculoskeletal conditions severely
affects patients’ quality of life. In humans, paracetamol
and non-steroidal anti-inflammatory drugs (NSAIDs) are
most often prescribed to treat OA pain, with some clini-
cians preferring paracetamol/opioid combinations or an
opioid alone, depending on patient age and other comor-
bidities (for example, renal disease, diabetes, hypertension,
gastrointestinal, etc.) [106]. These medications may be ap-
propriate for the majority of patients, however, there are
some barriers to optimal pain management, including pa-
tient compliance, self-medication and lack of monitoring
by the clinician [106]. It is recognised that opioid misuse
in the U.S. has reached epidemic proportions [107], for
which the U.S. Department for Health and Human Ser-
vices has announced a new combative strategy [108].
Therefore, other treatment options may need to be con-
sidered if the pain cannot be appropriately controlled or if
the prescription of particular medications is problematic
in that country.
One health, OA and learning from studies in the
canine species
OA is also a commonly presented condition in dogs.
The recommended conservative management in this
species usually includes nutritional management and
weight control (with considered exercise options), along-
side pain management/disease modifying agents and
physical rehabilitation [109]. The usual approach when a
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canine presents with OA is to prioritise weight loss and
exercise, as the canine patients are often overweight or
obese, thus weight management is seen as a priority in
these cases [110]. Similarly, it is becoming increasingly
recognised that obesity is a risk factor for OA in
humans, with increasing prevalence in the last few de-
cades [111, 112]. Where canine pain is managed, the
usual treatments are similar to human medicine and in-
clude opioids and NSAIDs. Systemic and intraarticular
corticosteroids have been shown to be effective for pain
management in dogs and horse, despite being less com-
monly used in these species, and may provide a protect-
ive articular effect [113, 114]. In contrast, intraarticular
corticosteroid injections for human knee osteoarthritis
have been shown to give similar reductions in pain as
the placebo injection [115]. The latter could be ex-
plained by a mechanical effect of the fluid volume being
injected. Research into musculoskeletal conditions in
veterinary species is lacking in quantitative markers of
evaluation, such as objective gait analysis. Despite lame-
ness scoring by a veterinarian (a semi-quantitative tool),
owner perception is often relied upon to determine pa-
tient improvement. The “caregiver placebo effect” is re-
ported on in veterinary literature, affecting both owner’s
and veterinary practitioner’s judgement when they are
assessing an animal’s lameness against an objective
measure [116]. Further research into quantitative bio-
mechanical markers in veterinary species is essential,
along with increased use of objective measures in clinical
practice.
In humans and veterinary species, the treatment regi-
mens are very similar with corticosteroids. The usual
dosing pattern would be one intraarticular injection
every six weeks, with no more than 3–4 per year.
Long-term steroid use (i.e. more often than four times
per year) is recommended to be avoided in all species
due to systemic side-effects [117]. NSAIDs are also
known for having side effects in the gastrointestinal sys-
tem, with potentially severe effects in the lower gastro-
intestinal tract, as well as in other systems [118].
Therefore, finding alternatives to these therapies for
high-risk patients seems to be the logical option. Some
possibilities may be topical NSAIDs, which have fewer
side effects [119] or other modalities such as photobio-
modulation (low level laser therapy; LLLT) [120]. Animal
studies suggest that at the right dose, laser therapy can
be more effective at modulating the inflammatory
process, than topical NSAIDs which treat pain alone
[120]. Treatment of the inflammatory processes may also
decrease the pain that is reported with many musculo-
skeletal disorders or injuries. Traditionally, people may
use cryotherapy or topical NSAIDs such as diclofenac
for treatment of acute musculoskeletal injuries. However,
a recent study showed that LLLT was more effective at
decreasing pro-inflammatory cytokine release in an ani-
mal model than topical diclofenac and cryotherapy
[121]. Other treatments such as acupuncture, ultrasound
and transcutaneous electrical nerve stimulation (TENS)
are known to be effective for pain relief in both human
and veterinary medicine, however, the methodological
quality of some studies has been questioned and com-
parisons between the studies show large heterogeneity
and significant publication bias [122]. For example, acu-
puncture has been shown to be effective for the short
term relief of pain [123]; TENS was shown to be inef-
fective for musculoskeletal pain [124, 125]; ultrasound
and shockwave therapy also do not appear to improve
pain significantly [126, 127]. However, there do seem to
be patient-reported beneficial effects of these treatments
and reduced lameness in animals, which may mean that
whilst there is no evidence for clinical mechanisms of
action of these treatments, some of them may be work-
ing to improve patient health. Further, NSAIDs, opioids
and topical steroids were found to be beneficial in the
short term for pain relief, but not over a longer time
period. In contrast, exercise therapy and psychosocial in-
terventions not only relieved pain but improved function
in a human primary care setting [122]. Psychosocial in-
terventions may include self-management, behavioural
and/or cognitive changes. These are longer-term therap-
ies, which may improve patient outcomes as patients be-
come empowered to manage their own conditions.
Physical rehabilitation will usually include several dif-
ferent techniques and modalities, in order to slow pro-
gression of the disease, improve patients’ activity levels
and, in turn, decrease their level of disability. Some tech-
niques used in rehabilitation include passive ranges of
motion, where the therapist will move or manipulate the
joint for the patient and thus increase the metabolism of
the tissues. Rehabilitation can also include therapeutic
exercises, which are controlled movements where the
patient will perform active ranges of motion (i.e. the pa-
tient is self-motivated to move), achieving the same tis-
sue metabolic and physical effects [128]. Rehabilitation
in this manner aims to ensure muscle tone is improved
and that joints are utilised effectively. Specifically, im-
proving muscle tone should decrease the rate of progres-
sion of the disease (as the joint becomes stabilised) and
hopefully decrease a patient’s pain levels. Whilst these
therapies will not cure arthritis, improving the joint
characteristics in this manner will enable the patient to
keep active for longer.
Patients can be referred to a specialist for physical
therapy and orthotics to improve posture and gait imbal-
ances, which may not only prevent but improve muscu-
loskeletal ailments that may ultimately result in injuries
to cartilage and soft tissues. Identifying the needs of a
patient before a musculoskeletal condition becomes an
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issue, for example, utilising workstation assessments
(usually implemented by an Occupational Health profes-
sional, under employer guidance) in order to improve
the ergonomics of items the patient uses every day and
then training the patient in the best use of these items,
will improve a patients’ posture and could lead to pre-
vention of musculoskeletal injuries. Incorporating
real-time visual feedback into the assessment of patient
behaviour has been shown to be an effective tool for im-
proving posture [129]. Increases in patient numbers re-
ferred for this preventative kind of therapy could reduce
patient presentations at a later stage for more serious
musculoskeletal complaints. This referral will only work
if the general practitioner is able to identify these imbal-
ances at an early stage.
It is clear that a holistic and individualised approach to
managing treatment in musculoskeletal conditions is ne-
cessary, with the input of multidisciplinary health profes-
sionals, including general practitioners, dieticians, physical
therapists and fitness specialists. Thus, the problem would
need to be assessed from multiple viewpoints and at a
much earlier stage with greater input from the patients
and their commitment if behaviour change is required.
Equally, this issue would also be more likely to fulfil pa-
tients’ needs and, most importantly, place greater em-
phasis on their medical background, lifestyle, any
co-morbidities and their family history and susceptibility
to developing musculoskeletal disease.
Current research approaches for musculoskeletal
diseases
Arthritis Research UK, recently rebranded as Versus Arth-
ritis, has presented a new approach plan towards arthritis
and related musculoskeletal conditions by providing a
wealth of information to the public, funding and undertak-
ing research, improving data collection and influencing re-
lated policies [41]. Whilst data on the levels of funding
received for different conditions can be difficult to obtain
for European countries, in the United States, musculoskel-
etal conditions received the least funding from the National
Institutes of Health Research compared to other conditions
such as cardiovascular disease or cancers (Fig. 3 a). Of those
musculoskeletal conditions funded, the largest proportion
went to investigating conditions resulting from injuries or
accidents (Fig. 3 b).
Understanding common diseases such as OA and RA
would help to develop better and more precise diagnostic
and prognostic tools, improve treatment management and
lead to the recommendation of effective preventive mea-
sures. There are currently few funding streams that enable
researchers to join together and work on all these aspects
of musculoskeletal health. A multidisciplinary approach
combining these factors could not only improve patient
diagnosis and outcomes but also help further our
understanding of disease progression. Current research on
musculoskeletal diseases is mainly focused on understand-
ing the mechanisms of disease to identify a better and
earlier diagnosis. At a cellular level this includes studies
on chondrocytes and synovial tissue as well as osteoblasts
[130–132]. Studies with animal models to investigate OA
are being widely used to understand the disease and its
symptoms such as pain [133–135]. Veterinary research is
important, not only on established animal models but
also on companion animals because species, such as rab-
bits, dogs and horses, are also commonly affected by simi-
lar musculoskeletal diseases with similar clinical signs to
humans [136, 137]. As these animals have a shorter life
span, this allows for observation of the complete process
of disease over a shorter time period.
There is also the opportunity when studying rare mus-
culoskeletal diseases, such as alkaptonuria (AKU), for re-
searchers to determine whether treatments developed
specifically for these can facilitate the development of
new therapies for the more common disorders. There
may also be common pathways in disease progression,
which may help understanding of how and why individ-
uals develop musculoskeletal problems [138].
In addition to the general population, there is also an in-
creasing need for more research in musculoskeletal condi-
tions affecting the military; in 2006 there were nearly three
quarters of a million reported musculoskeletal injuries or
conditions in the US military [139]. This sector of the popu-
lation is an interesting target for research studies as it has a
high incidence of musculoskeletal injuries. For example, it
has been shown that conservative physical therapy is a valu-
able first approach for musculoskeletal conditions in a US
naval department [140]. On the other hand, the vast major-
ity of US army active soldiers are being prescribed NSAIDs,
where more investigation is needed to stablish the pros and
cons of this practice in that population [141]. These contra-
dictions could be tackled by increasing the number of
high-quality research studies and thus establish new guide-
lines and recommendations for the improved management
of musculoskeletal health in the military.
Until the underlying mechanisms of these diseases are
revealed and important details that give us more infor-
mation are clarified, little can be done in terms of devel-
oping new treatment options. Although it is important
to work on a preventative approach, treatment still
needs to be optimised to reduce pain and disability, es-
pecially given the rising numbers of elderly people as
well as an unfit, sedentary and overweight population.
Conclusion
The burden of musculoskeletal diseases will only increase
with an increasing ageing population and an increased
number of people not taking diet, lifestyle, health and
physical activity seriously. A pragmatic multidisciplinary
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Fig. 3 The burden of musculoskeletal disease in the United States and the funding gap for research on musculoskeletal conditions (2009–2013).
a. Despite the major health care burden presented by musculoskeletal conditions, research funding falls well below that of most other
conditions. Injury research accounted for half of the musculoskeletal condition research dollars ($4 billion) from NIH for the years 2009 to 2013.
Funding for arthritis research is second, at $1.4 billion, followed by osteoporosis ($965 million). These numbers are well below the $8.6 to $55.2
billion in funding for the top 25 NIH research areas, dominated by cancer, cardiovascular disease and other disease areas. b. Research funding
allocated to different musculoskeletal conditions by NIAMS. The data clearly indicate that musculoskeletal conditions receive less funding support
compared to other disease areas despite the heavy burden on healthcare systems worldwide
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approach to treatment and prevention is needed to tackle
these problems; including raising public awareness of risk
factors and improving the understanding of these ap-
proaches within the medical and scientific community.
Behaviour change and patient participation is absolutely
crucial for success. We must make use of efficient diag-
nostic tools available and develop new ones that enable
earlier identification of MSK disease; and we need to in-
vestigate the mechanisms of disease progression that will
lead to preventive measures and individually tailored and
more holistic treatment programmes.
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